YOURx Health review

What it is

YOURx Health is a compounded-medication telehealth platform running its clinical layer on the MD Integrations network, a recognised white-label provider platform used across the industry. Its treatments page carries a per-product price list spanning weight loss (compounded semaglutide injection $179/mo and tirzepatide injection $199/mo, plus rapid-dissolve oral tablets of each at $159 and $179), longevity and recovery (NAD+ injection $225/mo, NAD+ nasal spray $199/mo, sermorelin $196/mo, glutathione $95/mo, B12+MIC $99/mo) and sexual health (a PT-141, oxytocin and tadalafil troche starting at $99.99/mo). Everything is self-pay; its FAQ states it does not accept medical insurance.

How it works

Video-gated and vendor-run. The site describes a physician video consultation, medication delivery, regular check-ins, lab monitoring and refills, with medical care and prescriptions delivered through the MD Integrations network — naming the clinical platform vendor is a small transparency point in its favour, because MD Integrations is checkable even though the individual prescriber is not. Lab work is flagged as required for certain prescriptions, which for a growth-hormone-axis or hormone product is the right posture. From there the disclosures run out. The legal entity operating the site is not disclosed anywhere; the footer gives a Beaumont, Texas location and a brand copyright and nothing more. No compounding pharmacy partner is named. No state availability list is published, and the homepage coverage counter is a JavaScript-animated element rather than a real number, which has historically rendered as a placeholder. No LegitScript, NABP .Pharmacy or PCAB accreditation is displayed — and on a site selling injectable prescriptions, the absence of all three at once is the single biggest gap here. Weigh the published price list against that: knowing what something costs is not the same as knowing who is making it.

Pricing transparency

The clearest thing about this platform, and a real improvement on the record. Sermorelin is listed at $196.00 per month and glutathione at $95.00 per month; NAD⁺ is priced by route at $199.00 for the nasal spray and $225.00 for the injection; the PT-141, oxytocin and tadalafil troche starts at $99.99 per month. Each is a flat per-product monthly figure with no stated dose ladder in either direction, so ask whether the price holds as your dose changes — the site says nothing either way. Everything is self-pay; the FAQ states verbatim that all products are available on a self-pay basis because it does not accept medical insurance at this time. For context only, the weight-loss line runs $179 and $199 a month for compounded semaglutide and tirzepatide injections and $159 and $179 for the oral rapid-dissolve tablets, with B12 included on the injections — but those are GLP-1 figures and neither is a sermorelin or NAD⁺ price. Two things the page does not tell you and you should ask: what the monthly shipment contains in milligrams, and whether the required lab work is billed separately from the medication.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The platform states its products are compounded and that prescriptions come through the MD Integrations clinician network, but it names no pharmacy, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, its four longevity products are not four equivalent purchases even though they sit in one price list. Sermorelin is a GHRH analogue that stimulates your own pituitary rather than supplying growth hormone — a real, well-described mechanism whose long-term human outcome data stays thin beyond short-term IGF-1 movement. Injected and intranasal NAD⁺ have no controlled human outcome trials at all, and pricing the nasal spray below the injection reflects manufacturing cost rather than any comparative evidence; the NAD⁺ forms with human trial data are the oral precursors NR and NMN, which raise a blood level rather than demonstrate an outcome. Injectable glutathione has essentially no controlled human outcome data behind the antioxidant and skin claims made for it. PT-141 is the exception in the other direction — bremelanotide is FDA-approved for one narrow indication, generalised hypoactive sexual desire disorder in premenopausal women, so a compounded troche prescribed to anyone else is off-label use of an approved molecule, and combining it with tadalafil and oxytocin in a single preparation is a formulation no trial has studied. Individual results vary.

Pros and watch-outs

The evidence behind what YOURx Health prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• NAD injections: how to get them near you or online, and what the evidence really says

  Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.

• NAD⁺ nasal spray: the delivery format with the least direct evidence

  Intranasal NAD⁺ is convenient and heavily marketed — but no controlled human trial shows the spray raises systemic or brain NAD⁺. A straight comparison with the better-studied routes.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

• PT-141 (bremelanotide): the evidence on a research-popular peptide that is actually FDA-approved

  Bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women, with phase-3 trial evidence. A straight read of what's proven — and where off-label use goes beyond it.

How YOURx Health compares

A few alternatives worth a look, depending on what you’re optimizing for.

• WWWhoosh Wellness

  NAD⁺ buyers who want the injection and the nasal spray priced identically and all-in

  See Whoosh Wellness →
• YOYourHealthRx

  Readers who want the route and vial size named before they discuss cost

  See YourHealthRx →
• PLPlexusDx

  NAD⁺ at a published all-in monthly price with check-ins and no membership on top

  See PlexusDx →